English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Radiofrequency ablation (RFA), one of several local ablative modalities gaining acceptance in the treatment of liver malignancies, is based on the induction of coagulative necrosis by delivering electrical energy to tissue using a shielded needle electrode. Though uncommon, complications may result from the percutaneous application of RFA, including tumor seeding associated with the needle tract. The seeding risk after percutaneous RFA for hepatocellular carcinoma (HCC) is approximately 0.6%. In general, the rate of tumor seeding resulting from RFA for HCC is 0%–2.8%.4-11 In Korea, omental and skin metastases, along the needle tract have been reported after RFA of HCC. However, tumor implantation in the ovaries after percutaneous RFA of HCC is rarely reported.16 We describe the first reported case of needle tract implantation of HCC in the ovary after percutaneous RFA.

A Case of needle-tract implantation of hepatocellular carcinoma in the ovary after radiofrequency ablation